{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T03:04:38Z","timestamp":1793156678913,"version":"4.5.0"},"reference-count":161,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","license":[{"start":{"date-parts":[[2020,12,14]],"date-time":"2020-12-14T00:00:00Z","timestamp":1607904000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver disease worldwide, placing an increasing burden on human health. NAFLD is a complex multifactorial disease involving genetic, metabolic, and environmental factors. It is closely associated with metabolic syndrome, obesity, and type 2 diabetes, of which insulin resistance is the main pathophysiological mechanism. Over the past few decades, investigation of the pathogenesis, diagnosis, and treatments has revealed different aspects of NAFLD, challenging the accuracy of definition and therapeutic strategy for the clinical practice. Recently, experts reach a consensus that NAFLD does not reflect the current knowledge, and metabolic (dysfunction) associated fatty liver disease (MAFLD) is suggested as a more appropriate term. The new definition puts increased emphasis on the important role of metabolic dysfunction in it. Herein, the shared features and potential changes in epidemiology, pathophysiology, diagnosis, and pharmacotherapy of the newly defined MAFLD, as compared with the formerly defined NAFLD, are reviewed for updating our understanding.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/cm9.0000000000001263","type":"journal-article","created":{"date-parts":[[2020,12,15]],"date-time":"2020-12-15T13:37:41Z","timestamp":1608039461000},"page":"8-19","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":93,"title":["MAFLD vs. NAFLD: shared features and potential changes in epidemiology, pathophysiology, diagnosis, and pharmacotherapy"],"prefix":"10.1097","volume":"134","author":[{"given":"Ying-Xin","family":"Xian","sequence":"first","affiliation":[{"name":"Department of Endocrinology and Metabolism, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong 510630, China"},{"name":"Guangdong Provincial Key Laboratory of Diabetology, Guangzhou, Guangdong 510630, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian-Ping","family":"Weng","sequence":"additional","affiliation":[{"name":"Guangdong Provincial Key Laboratory of Diabetology, Guangzhou, Guangdong 510630, China"},{"name":"Department of Endocrinology of the First Affiliated Hospital, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui 230001, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fen","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong 510630, China"},{"name":"Guangdong Provincial Key Laboratory of Diabetology, Guangzhou, Guangdong 510630, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2021,1,5]]},"reference":[{"key":"R1-20250603","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/nrgastro.2017.109","article-title":"Global burden of NAFLD and NASH: Trends, predictions, risk factors and prevention","volume":"15","author":"Younossi","year":"2018","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"R2-20250603","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/hep.29367","article-title":"The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases","volume":"67","author":"Chalasani","year":"2018","journal-title":"Hepatology"},{"key":"R3-20250603","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/S2213-8587(14)70032-4","article-title":"Non-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome","volume":"2","author":"Yki-Jarvinen","year":"2014","journal-title":"Lancet Diabetes Endocrinol"},{"key":"R4-20250603","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1111\/imj.14709","article-title":"Non-alcoholic fatty liver disease (NAFLD): A review of epidemiology, risk factors, diagnosis and management","volume":"50","author":"Huang","year":"2020","journal-title":"Intern Med J"},{"key":"R5-20250603","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.1002\/hep.30251","article-title":"Global perspectives on nonalcoholic fatty liver disease and nonalcoholic steatohepatitis","volume":"69","author":"Younossi","year":"2019","journal-title":"Hepatology"},{"key":"R6-20250603","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1053\/j.gastro.2019.11.312","article-title":"MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease","volume":"158","author":"Eslam","year":"2020","journal-title":"Gastroenterology"},{"key":"R7-20250603","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.jhep.2020.03.039","article-title":"A new definition for metabolic associated fatty liver disease: an international expert consensus statement","volume":"73","author":"Eslam","year":"2020","journal-title":"J Hepatol"},{"key":"R8-20250603","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/hep.28431","article-title":"Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes","volume":"64","author":"Younossi","year":"2016","journal-title":"Hepatology"},{"key":"R9-20250603","doi-asserted-by":"crossref","first-page":"S47","DOI":"10.1016\/j.jhep.2014.12.012","article-title":"NAFLD: a multisystem disease","volume":"62","author":"Byrne","year":"2015","journal-title":"J Hepatol"},{"key":"R10-20250603","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.jhep.2019.06.021","article-title":"The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: a systematic review and meta-analysis","volume":"71","author":"Younossi","year":"2019","journal-title":"J Hepatol"},{"key":"R11-20250603","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s12072-020-10023-3","article-title":"The epidemiology of NAFLD in Mainland China with analysis by adjusted gross regional domestic product: a meta-analysis","volume":"12","author":"Wu","year":"2020","journal-title":"Hepatol Int"},{"key":"R12-20250603","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1002\/hep.31150","article-title":"Epidemiological features of NAFLD from 1999 to 2018 in China","volume":"71","author":"Zhou","year":"2020","journal-title":"Hepatology"},{"key":"R13-20250603","doi-asserted-by":"crossref","first-page":"226","DOI":"10.3803\/EnM.2019.34.3.226","article-title":"Nonalcoholic fatty liver disease and diabetes: An epidemiological perspective","volume":"34","author":"Rhee","year":"2019","journal-title":"Endocrinol Metab (Seoul)"},{"key":"R14-20250603","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.metabol.2018.11.014","article-title":"Obesity and nonalcoholic fatty liver disease: from pathophysiology to therapeutics","volume":"92","author":"Polyzos","year":"2019","journal-title":"Metabolism"},{"key":"R15-20250603","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/S2468-1253(19)30039-1","article-title":"Prevalence, incidence, and outcome of non-alcoholic fatty liver disease in Asia, 1999-2019: a systematic review and meta-analysis","volume":"4","author":"Li","year":"2019","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"R16-20250603","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1136\/gut.2010.213553","article-title":"Components of metabolic syndrome are independent predictors of mortality in patients with chronic liver disease: a population-based study","volume":"59","author":"Stepanova","year":"2010","journal-title":"Gut"},{"key":"R17-20250603","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.cld.2013.09.006","article-title":"The impact of obesity and metabolic syndrome on alcoholic liver disease","volume":"18","author":"Chiang","year":"2014","journal-title":"Clin Liver Dis"},{"key":"R18-20250603","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1097\/01.MP.0000042420.21088.C7","article-title":"Concurrence of histologic features of steatohepatitis with other forms of chronic liver disease","volume":"16","author":"Brunt","year":"2003","journal-title":"Mod Pathol"},{"key":"R19-20250603","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1002\/hep.30857","article-title":"Nonalcoholic steatohepatitis is associated with liver-related outcomes and all-cause mortality in chronic hepatitis B","volume":"71","author":"Choi","year":"2020","journal-title":"Hepatology"},{"key":"R20-20250603","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1111\/liv.14548","article-title":"Comparison of MAFLD and NAFLD diagnostic criteria in real world","volume":"40","author":"Lin","year":"2020","journal-title":"Liver Int"},{"key":"R21-20250603","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/ajg.2016.318","article-title":"Clinical and metabolic characterization of lean Caucasian subjects with non-alcoholic fatty liver","volume":"112","author":"Feldman","year":"2017","journal-title":"Am J Gastroenterol"},{"key":"R22-20250603","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1002\/hep.30908","article-title":"Lean NAFLD: A distinct entity shaped by differential metabolic adaptation","volume":"71","author":"Chen","year":"2020","journal-title":"Hepatology"},{"key":"R23-20250603","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/S2468-1253(20)30077-7","article-title":"Global prevalence, incidence, and outcomes of non-obese or lean non-alcoholic fatty liver disease: a systematic review and meta-analysis","volume":"5","author":"Ye","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"R24-20250603","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.3748\/wjg.v26.i15.1792","article-title":"Prevalence, clinical characteristics, risk factors, and indicators for lean Chinese adults with nonalcoholic fatty liver disease","volume":"26","author":"Zeng","year":"2020","journal-title":"World J Gastroenterol"},{"key":"R25-20250603","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/S0016-5085(98)70599-2","article-title":"Steatohepatitis: a tale of two \u201chits\u201d?","volume":"114","author":"Day","year":"1998","journal-title":"Gastroenterology"},{"key":"R26-20250603","doi-asserted-by":"crossref","first-page":"2974","DOI":"10.3748\/wjg.v24.i27.2974","article-title":"Pathogenesis of non-alcoholic fatty liver disease in children and adolescence: from \u201ctwo hit theory\u201d to \u201cmultiple hit model\u201d","volume":"24","author":"Fang","year":"2018","journal-title":"World J Gastroenterol"},{"key":"R27-20250603","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1097\/CM9.0000000000000981","article-title":"From NAFLD to MAFLD: a \u201credefining\u201d moment for fatty liver disease","volume":"133","author":"Zheng","year":"2020","journal-title":"Chin Med J"},{"key":"R28-20250603","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1111\/dom.12973","article-title":"Non-alcoholic fatty liver disease (NAFLD) prevalence and its metabolic associations in patients with type 1 diabetes and type 2 diabetes","volume":"19","author":"Cusi","year":"2017","journal-title":"Diabetes Obes Metab"},{"key":"R29-20250603","doi-asserted-by":"crossref","first-page":"3441","DOI":"10.1073\/pnas.0914798107","article-title":"Bifurcation of insulin signaling pathway in rat liver: mTORC1 required for stimulation of lipogenesis, but not inhibition of gluconeogenesis","volume":"107","author":"Li","year":"2010","journal-title":"Proc Natl Acad Sci USA"},{"key":"R30-20250603","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.jhep.2017.09.003","article-title":"Genetics and epigenetics of NAFLD and NASH: clinical impact","volume":"68","author":"Eslam","year":"2018","journal-title":"J Hepatol"},{"key":"R31-20250603","doi-asserted-by":"crossref","first-page":"e1001324","DOI":"10.1371\/journal.pgen.1001324","article-title":"Genome-wide association analysis identifies variants associated with nonalcoholic fatty liver disease that have distinct effects on metabolic traits","volume":"7","author":"Speliotes","year":"2011","journal-title":"Plos Genet"},{"key":"R32-20250603","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1038\/ng.2901","article-title":"Exome-wide association study identifies a TM6SF2 variant that confers susceptibility to nonalcoholic fatty liver disease","volume":"46","author":"Kozlitina","year":"2014","journal-title":"Nat Genet"},{"key":"R33-20250603","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1056\/NEJMoa1712191","article-title":"A protein-truncating HSD17B13 variant and protection from chronic liver disease","volume":"378","author":"Abul-Husn","year":"2018","journal-title":"N Engl J Med"},{"key":"R34-20250603","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1038\/s41588-018-0084-1","article-title":"Refining the accuracy of validated target identification through coding variant fine-mapping in type 2 diabetes","volume":"50","author":"Mahajan","year":"2018","journal-title":"Nat Genet"},{"key":"R35-20250603","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1172\/JCI30706","article-title":"Mechanisms by which common variants in the TCF7L2 gene increase risk of type 2 diabetes","volume":"117","author":"Lyssenko","year":"2007","journal-title":"J Clin Invest"},{"key":"R36-20250603","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.2337\/db12-0858","article-title":"Sterol regulatory element-binding factor 2 (SREBF-2) predicts 7-year NAFLD incidence and severity of liver disease and lipoprotein and glucose dysmetabolism","volume":"62","author":"Musso","year":"2013","journal-title":"Diabetes"},{"key":"R37-20250603","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1002\/hep.22142","article-title":"Adiponectin gene polymorphisms modulate acute adiponectin response to dietary fat: Possible pathogenetic role in NASH","volume":"47","author":"Musso","year":"2008","journal-title":"Hepatology"},{"key":"R38-20250603","first-page":"12","article-title":"Association of the SH2B1 rs7359397 gene polymorphism with steatosis severity in subjects with obesity and non-alcoholic fatty liver disease","author":"Perez-Diaz-Del-Campo","year":"2020","journal-title":"Nutrients"},{"key":"R39-20250603","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1002\/hep.22659","article-title":"Transcription factor 7-like 2 polymorphism modulates glucose and lipid homeostasis, adipokine profile, and hepatocyte apoptosis in NASH","volume":"49","author":"Musso","year":"2009","journal-title":"Hepatology"},{"key":"R40-20250603","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.gene.2013.09.012","article-title":"Genetic association of ADIPOQ gene variants with type 2 diabetes, obesity and serum adiponectin levels in south Indian population","volume":"532","author":"Ramya","year":"2013","journal-title":"Gene"},{"key":"R41-20250603","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1038\/ng.3417","article-title":"A genome-wide association study confirms PNPLA3 and identifies TM6SF2 and MBOAT7 as risk loci for alcohol-related cirrhosis","volume":"47","author":"Buch","year":"2015","journal-title":"Nat Genet"},{"key":"R42-20250603","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1002\/hep.28475","article-title":"Diverse impacts of the rs58542926 E167K variant in TM6SF2 on viral and metabolic liver disease phenotypes","volume":"64","author":"Eslam","year":"2016","journal-title":"Hepatology"},{"key":"R43-20250603","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1053\/j.gastro.2016.01.032","article-title":"The MBOAT7-TMC4 variant rs641738 increases risk of nonalcoholic fatty liver disease in individuals of European descent","volume":"150","author":"Mancina","year":"2016","journal-title":"Gastroenterology"},{"key":"R44-20250603","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.2337\/db07-1807","article-title":"The common P446L polymorphism in GCKR inversely modulates fasting glucose and triglyceride levels and reduces type 2 diabetes risk in the DESIR prospective general French population","volume":"57","author":"Vaxillaire","year":"2008","journal-title":"Diabetes"},{"key":"R45-20250603","first-page":"10","article-title":"Dissociation of fatty liver and insulin resistance in I148M PNPLA3 carriers: Differences in diacylglycerol (DAG) FA18:1 lipid species as a possible explanation","author":"Franko","year":"2018","journal-title":"Nutrients"},{"key":"R46-20250603","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.jhep.2017.02.014","article-title":"Impaired hepatic lipid synthesis from polyunsaturated fatty acids in TM6SF2 E167K variant carriers with NAFLD","volume":"67","author":"Luukkonen","year":"2017","journal-title":"J Hepatol"},{"key":"R47-20250603","first-page":"109","article-title":"Carbohydrate intake and nonalcoholic fatty liver disease: Fructose as a weapon of mass destruction","volume":"4","author":"Basaranoglu","year":"2015","journal-title":"Hepatobiliary Surg Nutr"},{"key":"R48-20250603","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1016\/j.jhep.2018.01.019","article-title":"Fructose and sugar: a major mediator of non-alcoholic fatty liver disease","volume":"68","author":"Jensen","year":"2018","journal-title":"J Hepatol"},{"key":"R49-20250603","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1002\/hep.26672","article-title":"Nonalcoholic fatty liver disease, hepatic insulin resistance, and type 2 diabetes","volume":"59","author":"Birkenfeld","year":"2014","journal-title":"Hepatology"},{"key":"R50-20250603","doi-asserted-by":"crossref","first-page":"3914","DOI":"10.1210\/jc.2003-031941","article-title":"Separate contribution of diabetes, total fat mass, and fat topography to glucose production, gluconeogenesis, and glycogenolysis","volume":"89","author":"Gastaldelli","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"R51-20250603","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1002\/hep.30083","article-title":"Diabetes, plasma glucose, and incidence of fatty liver, cirrhosis, and liver cancer: a prospective study of 0.5 million people","volume":"68","author":"Pang","year":"2018","journal-title":"Hepatology"},{"key":"R52-20250603","doi-asserted-by":"crossref","first-page":"e76161","DOI":"10.1371\/journal.pone.0076161","article-title":"Glycemic variability is an independent predictive factor for development of hepatic fibrosis in nonalcoholic fatty liver disease","volume":"8","author":"Hashiba","year":"2013","journal-title":"PloS One"},{"key":"R53-20250603","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1016\/j.jhep.2011.12.011","article-title":"Predictors for incidence and remission of NAFLD in the general population during a seven-year prospective follow-up","volume":"56","author":"Zelber-Sagi","year":"2012","journal-title":"J Hepatol"},{"key":"R54-20250603","first-page":"9","article-title":"Glucose and lipid dysmetabolism in a rat model of prediabetes induced by a high-sucrose diet","author":"Burgeiro","year":"2017","journal-title":"Nutrients"},{"key":"R55-20250603","doi-asserted-by":"crossref","first-page":"472432","DOI":"10.1155\/2013\/472432","article-title":"Roles for PI3K\/AKT\/PTEN pathway in cell signaling of nonalcoholic fatty liver disease","volume":"2013","author":"Matsuda","year":"2013","journal-title":"ISRN Endocrinol"},{"key":"R56-20250603","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.jnutbio.2013.10.014","article-title":"Liquid fructose down-regulates liver insulin receptor substrate 2 and gluconeogenic enzymes by modifying nutrient sensing factors in rats","volume":"25","author":"Rebollo","year":"2014","journal-title":"J Nutr Biochem"},{"key":"R57-20250603","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1007\/s12020-020-02268-7","article-title":"Insulin resistance is related with liver fibrosis in type 2 diabetic patients with non-alcoholic fatty liver disease proven biopsy and Mediterranean diet pattern as a protective factor","volume":"68","author":"Aller","year":"2020","journal-title":"Endocrine"},{"key":"R58-20250603","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1161\/CIRCRESAHA.119.315896","article-title":"Metabolic inflammation and insulin resistance in obesity","volume":"126","author":"Wu","year":"2020","journal-title":"Circ Res"},{"key":"R59-20250603","first-page":"777","article-title":"Non-alcoholic fatty liver disease: a starting point of the onset of type 2 diabetes mellitus? (in Chinese)","volume":"48","author":"Weng","year":"2018","journal-title":"J Univ Sci Tech China"},{"key":"R60-20250603","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1172\/JCI29069","article-title":"Inflammation and insulin resistance","volume":"116","author":"Shoelson","year":"2006","journal-title":"J Clin Invest"},{"key":"R61-20250603","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1038\/nri2925","article-title":"Type 2 diabetes as an inflammatory disease","volume":"11","author":"Donath","year":"2011","journal-title":"Nat Rev Immunol"},{"key":"R62-20250603","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1038\/nm1166","article-title":"Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappaB","volume":"11","author":"Cai","year":"2005","journal-title":"Nat Med"},{"key":"R63-20250603","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.tem.2015.05.007","article-title":"Targeting endoplasmic reticulum stress in insulin resistance","volume":"26","author":"Salvad\u00f3","year":"2015","journal-title":"Trends Endocrinol Metab"},{"key":"R64-20250603","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1530\/JME-15-0101","article-title":"Glucose fluctuation increased hepatocyte apoptosis under lipotoxicity and the involvement of mitochondrial permeability transition opening","volume":"55","author":"Yin","year":"2015","journal-title":"J Mol Endocrinol"},{"key":"R65-20250603","doi-asserted-by":"crossref","first-page":"65","DOI":"10.3945\/ajcn.114.094730","article-title":"Proton magnetic resonance spectroscopy reveals increased hepatic lipid content after a single high-fat meal with no additional modulation by added protein","volume":"101","author":"Lindeboom","year":"2015","journal-title":"Am J Clin Nutr"},{"key":"R66-20250603","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1007\/s00125-013-2913-1","article-title":"Distinct patterns of tissue-specific lipid accumulation during the induction of insulin resistance in mice by high-fat feeding","volume":"56","author":"Turner","year":"2013","journal-title":"Diabetologia"},{"key":"R67-20250603","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.2337\/dc19-2331","article-title":"Intrahepatic fat and postprandial glycemia increase after consumption of a diet enriched in saturated fat compared with free sugars","volume":"43","author":"Parry","year":"2020","journal-title":"Diabetes Care"},{"key":"R68-20250603","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1172\/JCI23621","article-title":"Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease","volume":"115","author":"Donnelly","year":"2005","journal-title":"J Clin Invest"},{"key":"R69-20250603","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1172\/JCI27300","article-title":"Reversal of diet-induced hepatic steatosis and hepatic insulin resistance by antisense oligonucleotide inhibitors of acetyl-CoA carboxylases 1 and 2","volume":"116","author":"Savage","year":"2006","journal-title":"J Clin Invest"},{"key":"R70-20250603","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.2337\/db06-0200","article-title":"Liver-specific inhibition of ChREBP improves hepatic steatosis and insulin resistance in ob\/ob mice","volume":"55","author":"Dentin","year":"2006","journal-title":"Diabetes"},{"issue":"(Suppl 2)","key":"R71-20250603","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1111\/j.1467-789X.2012.01035.x","article-title":"Visceral fat and metabolic inflammation: the portal theory revisited","volume":"13","author":"Item","year":"2012","journal-title":"Obes Rev"},{"key":"R72-20250603","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.tips.2017.04.004","article-title":"Roles of diacylglycerols and ceramides in hepatic insulin resistance","volume":"38","author":"Petersen","year":"2017","journal-title":"Trends Pharmacol Sci"},{"key":"R73-20250603","doi-asserted-by":"crossref","first-page":"16381","DOI":"10.1073\/pnas.1113359108","article-title":"Cellular mechanism of insulin resistance in nonalcoholic fatty liver disease","volume":"108","author":"Kumashiro","year":"2011","journal-title":"Proc Natl Acad Sci USA"},{"key":"R74-20250603","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1016\/j.celrep.2017.05.035","article-title":"Hepatic diacylglycerol-associated protein kinase C \u03b5 translocation links hepatic steatosis to hepatic insulin resistance in humans","volume":"19","author":"Ter Horst","year":"2017","journal-title":"Cell Rep"},{"key":"R75-20250603","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1002\/hep.30765","article-title":"Hepatocyte deletion of triglyceride-synthesis enzyme Acyl CoA: Diacylglycerol acyltransferase 2 reduces steatosis without increasing inflammation or fibrosis in mice","volume":"70","author":"Gluchowski","year":"2019","journal-title":"Hepatology"},{"key":"R76-20250603","doi-asserted-by":"crossref","first-page":"5748","DOI":"10.1073\/pnas.1103451108","article-title":"Hepatic insulin resistance in mice with hepatic overexpression of diacylglycerol acyltransferase 2","volume":"108","author":"Jornayvaz","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R77-20250603","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1111\/j.1872-034X.2011.00934.x","article-title":"High fat diet induced hepatic steatosis and insulin resistance: role of dysregulated ceramide metabolism","volume":"42","author":"Longato","year":"2012","journal-title":"Hepatol Res"},{"key":"R78-20250603","doi-asserted-by":"crossref","first-page":"665","DOI":"10.3389\/fendo.2019.00665","article-title":"Inhibiting ceramide synthesis attenuates hepatic steatosis and fibrosis in rats with non-alcoholic fatty liver disease","volume":"10","author":"Jiang","year":"2019","journal-title":"Front Endocrinol (Lausanne)"},{"key":"R79-20250603","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.3389\/fphys.2019.01607","article-title":"Chronic adipose tissue inflammation linking obesity to insulin resistance and type 2 diabetes","volume":"10","author":"Zatterale","year":"2019","journal-title":"Front Physiol"},{"key":"R80-20250603","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.orcp.2016.03.009","article-title":"Body mass index and the visceral adipose tissue expression of IL-6 and TNF-alpha are associated with the morphological severity of non-alcoholic fatty liver disease in individuals with class III obesity","volume":"12","author":"Jorge","year":"2018","journal-title":"Obes Res Clin Pract"},{"key":"R81-20250603","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.jhep.2017.11.014","article-title":"Lipotoxicity and the gut-liver axis in NASH pathogenesis","volume":"68","author":"Marra","year":"2018","journal-title":"J Hepatol"},{"key":"R82-20250603","first-page":"39","article-title":"Liver fibrosis in the context of nonalcoholic steatohepatitis: the role of adipokines","volume":"64","author":"Di Maira","year":"2018","journal-title":"Minerva Gastroenterol Dietol"},{"key":"R83-20250603","doi-asserted-by":"crossref","first-page":"259","DOI":"10.3389\/fendo.2020.00259","article-title":"Macrophage subsets in obesity, aligning the liver and adipose tissue","volume":"11","author":"Remmerie","year":"2020","journal-title":"Front Endocrinol (Lausanne)"},{"key":"R84-20250603","doi-asserted-by":"crossref","first-page":"187","DOI":"10.3727\/105221619X15553433838609","article-title":"Nonalcoholic fatty liver disease: an update on the diagnosis","volume":"19","author":"Zhang","year":"2019","journal-title":"Gene Expr"},{"key":"R85-20250603","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1002\/hep.24452","article-title":"Diagnostic accuracy and reliability of ultrasonography for the detection of fatty liver: a meta-analysis","volume":"54","author":"Hernaez","year":"2011","journal-title":"Hepatology"},{"key":"R86-20250603","doi-asserted-by":"crossref","first-page":"245","DOI":"10.7861\/clinmedicine.18-3-245","article-title":"Non-alcoholic fatty liver disease","volume":"18","author":"Maurice","year":"2018","journal-title":"Clin Med (Lond)"},{"key":"R87-20250603","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.cld.2017.08.005","article-title":"Radiologic imaging in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis","volume":"22","author":"Esterson","year":"2018","journal-title":"Clin Liver Dis"},{"key":"R88-20250603","doi-asserted-by":"crossref","first-page":"290","DOI":"10.3350\/cmh.2017.0042","article-title":"Imaging evaluation of non-alcoholic fatty liver disease: Focused on quantification","volume":"23","author":"Lee","year":"2017","journal-title":"Clin Mol Hepatol"},{"key":"R89-20250603","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1053\/j.gastro.2015.11.048","article-title":"Magnetic resonance imaging more accurately classifies steatosis and fibrosis in patients with nonalcoholic fatty liver disease than transient elastography","volume":"150","author":"Imajo","year":"2016","journal-title":"Gastroenterology"},{"key":"R90-20250603","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1016\/j.jdiacomp.2016.05.014","article-title":"Factors associated with significant liver steatosis and fibrosis as assessed by transient elastography in patients with one or more components of the metabolic syndrome","volume":"30","author":"Mikolasevic","year":"2016","journal-title":"J Diabetes Complications"},{"key":"R91-20250603","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1111\/liv.13481","article-title":"Concomitant screening for liver fibrosis and steatosis in French type 2 diabetic patients using Fibroscan","volume":"37","author":"Roulot","year":"2017","journal-title":"Liver Int"},{"key":"R92-20250603","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1111\/jgh.13857","article-title":"Asia-pacific working party on non-alcoholic fatty liver disease guidelines 2017-part 1: definition, risk factors and assessment","volume":"33","author":"Wong","year":"2018","journal-title":"J Gastroenterol Hepatol"},{"key":"R93-20250603","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.7314\/APJCP.2015.16.5.1789","article-title":"Non-alcoholic fatty liver disease (NAFLD) and significant hepatic fibrosis defined by non-invasive assessment in patients with type 2 diabetes","volume":"16","author":"Sobhonslidsuk","year":"2015","journal-title":"Asian Pac J Cancer Prev"},{"key":"R94-20250603","doi-asserted-by":"crossref","first-page":"159","DOI":"10.3390\/diagnostics10030159","article-title":"Non-alcoholic fatty liver disease in patients with type 2 diabetes: evaluation of hepatic fibrosis and steatosis using Fibroscan","volume":"10","author":"Tuong","year":"2020","journal-title":"Diagnostics (Basel)"},{"key":"R95-20250603","doi-asserted-by":"crossref","first-page":"243","DOI":"10.3803\/EnM.2020.35.2.243","article-title":"Noninvasive evaluation of nonalcoholic fatty liver disease","volume":"35","author":"Lee","year":"2020","journal-title":"Endocrinol Metab (Seoul)"},{"key":"R96-20250603","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.jhep.2015.04.006","article-title":"Asociacion Latinoamericana para el Estudio del Higado. EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis","volume":"63","year":"2015","journal-title":"J Hepatol"},{"key":"R97-20250603","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1136\/jim-2018-000864","article-title":"Performance of the SteatoTest, ActiTest, NashTest and FibroTest in a multiethnic cohort of patients with type 2 diabetes mellitus","volume":"67","author":"Bril","year":"2019","journal-title":"J Investig Med"},{"key":"R98-20250603","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.jfma.2019.03.016","article-title":"A community-based study on the application of fatty liver index in screening subjects with nonalcoholic fatty liver disease","volume":"119","author":"Chen","year":"2020","journal-title":"J Formos Med Assoc"},{"key":"R99-20250603","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.clinre.2019.04.002","article-title":"The visceral adiposity index is a predictor of incident nonalcoholic fatty liver disease: a population-based longitudinal study","volume":"44","author":"Okamura","year":"2020","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"R100-20250603","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1089\/omi.2019.0035","article-title":"Novel serum biomarkers for noninvasive diagnosis and screening of nonalcoholic fatty liver disease-related hepatic fibrosis","volume":"23","author":"Lin","year":"2019","journal-title":"Omics"},{"key":"R101-20250603","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1186\/s12876-020-01334-8","article-title":"Efficacy of serum miRNA test as a non-invasive method to diagnose nonalcoholic steatohepatitis: a systematic review and meta-analysis","volume":"20","author":"Xin","year":"2020","journal-title":"BMC Gastroenterol"},{"key":"R102-20250603","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.cld.2017.08.006","article-title":"The use of liver biopsy in nonalcoholic fatty liver disease: when to biopsy and in whom","volume":"22","author":"Gunn","year":"2018","journal-title":"Clin Liver Dis"},{"key":"R103-20250603","doi-asserted-by":"crossref","first-page":"187","DOI":"10.3727\/105221619X15553433838609","article-title":"Nonalcoholic fatty liver disease: An update on the diagnosis","volume":"19","author":"Zhang","year":"2019","journal-title":"Gene Expr"},{"issue":"(Suppl 1)","key":"R104-20250603","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1111\/liv.13658","article-title":"Diagnosis of non-alcoholic fatty liver disease\/non-alcoholic steatohepatitis: non-invasive tests are enough","volume":"38","author":"Castera","year":"2018","journal-title":"Liver Int"},{"key":"R105-20250603","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1136\/flgastro-2018-101139","article-title":"Medical liver biopsy: background, indications, procedure and histopathology","volume":"11","author":"Boyd","year":"2020","journal-title":"Frontline Gastroenterol"},{"key":"R106-20250603","doi-asserted-by":"crossref","first-page":"154203","DOI":"10.1016\/j.metabol.2020.154203","article-title":"Current and emerging pharmacological options for the treatment of nonalcoholic steatohepatitis","author":"Polyzos","year":"2020","journal-title":"Metabolism"},{"key":"R107-20250603","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1007\/s12325-019-00898-6","article-title":"Pharmacological treatment for non-alcoholic fatty liver disease","volume":"36","author":"Francque","year":"2019","journal-title":"Adv Ther"},{"key":"R108-20250603","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1586\/17474124.2015.965143","article-title":"Diagnosis and management of cardiovascular risk in nonalcoholic fatty liver disease","volume":"9","author":"Lonardo","year":"2015","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"R109-20250603","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1056\/NEJMra041001","article-title":"Thiazolidinediones","volume":"351","author":"Yki-J\u00e4rvinen","year":"2004","journal-title":"N Engl J Med"},{"key":"R110-20250603","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1056\/NEJMoa0907929","article-title":"Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis","volume":"362","author":"Sanyal","year":"2010","journal-title":"N Engl J Med"},{"key":"R111-20250603","doi-asserted-by":"crossref","first-page":"305","DOI":"10.7326\/M15-1774","article-title":"Long-term pioglitazone treatment for patients with nonalcoholic steatohepatitis and prediabetes or type 2 diabetes mellitus: a randomized trial","volume":"165","author":"Cusi","year":"2016","journal-title":"Ann Intern Med"},{"key":"R112-20250603","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.2337\/dc19-0167","article-title":"Role of vitamin E for nonalcoholic steatohepatitis in patients with type 2 diabetes: a randomized controlled trial","volume":"42","author":"Bril","year":"2019","journal-title":"Diabetes Care"},{"key":"R113-20250603","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s11892-013-0378-8","article-title":"The future of thiazolidinedione therapy in the management of type 2 diabetes mellitus","volume":"13","author":"Yau","year":"2013","journal-title":"Curr Diab Rep"},{"key":"R114-20250603","doi-asserted-by":"crossref","first-page":"c5702","DOI":"10.1136\/bmj.c5702","article-title":"Effects of vitamin E on stroke subtypes: meta-analysis of randomised controlled trials","volume":"341","author":"Sch\u00fcrks","year":"2010","journal-title":"BMJ"},{"key":"R115-20250603","doi-asserted-by":"crossref","first-page":"S73","DOI":"10.2337\/dc18-S008","article-title":"Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes-2018","volume":"41","year":"2018","journal-title":"Diabetes Care"},{"key":"R116-20250603","doi-asserted-by":"crossref","first-page":"57","DOI":"10.3892\/br.2012.18","article-title":"Metformin in non-alcoholic fatty liver disease: a systematic review and meta-analysis","volume":"1","author":"Li","year":"2013","journal-title":"Biomed Rep"},{"key":"R117-20250603","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1007\/s00125-017-4342-z","article-title":"The mechanisms of action of metformin","volume":"60","author":"Rena","year":"2017","journal-title":"Diabetologia"},{"key":"R118-20250603","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1111\/apt.15331","article-title":"Long-term metformin use may improve clinical outcomes in diabetic patients with non-alcoholic steatohepatitis and bridging fibrosis or compensated cirrhosis","volume":"50","author":"Vilar-Gomez","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"key":"R119-20250603","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/s42000-018-0021-9","article-title":"The effect of antidiabetic medications on non-alcoholic fatty liver disease (NAFLD)","volume":"17","author":"Iogna","year":"2018","journal-title":"Hormones (Athens)"},{"key":"R120-20250603","doi-asserted-by":"crossref","first-page":"154001","DOI":"10.1016\/j.metabol.2019.154001","article-title":"Effects of newer antidiabetic drugs on nonalcoholic fatty liver and steatohepatitis: think out of the box!","volume":"101","author":"Ranjbar","year":"2019","journal-title":"Metabolism"},{"key":"R121-20250603","doi-asserted-by":"crossref","first-page":"487","DOI":"10.2337\/dci19-0066","article-title":"2019 Update to: management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)","volume":"43","author":"Buse","year":"2020","journal-title":"Diabetes Care"},{"key":"R122-20250603","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/S2213-8587(19)30249-9","article-title":"Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials","volume":"7","author":"Kristensen","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"R123-20250603","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1177\/0004563216648250","article-title":"Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomized, placebo-controlled phase 2 study","volume":"53","author":"Cegla","year":"2016","journal-title":"Ann Clin Biochem"},{"key":"R124-20250603","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1111\/hepr.12351","article-title":"Pilot study of liraglutide effects in non-alcoholic steatohepatitis and non-alcoholic fatty liver disease with glucose intolerance in Japanese patients (LEAN-J)","volume":"45","author":"Eguchi","year":"2015","journal-title":"Hepatol Res"},{"key":"R125-20250603","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S2213-8587(18)30024-X","article-title":"Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): A randomised, open-label, phase 3b trial","volume":"6","author":"Pratley","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"key":"R126-20250603","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1111\/apt.15316","article-title":"Effect of semaglutide on liver enzymes and markers of inflammation in subjects with type 2 diabetes and\/or obesity","volume":"50","author":"Newsome","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"key":"R127-20250603","article-title":"A systematic review of newer antidiabetic agents in the treatment of nonalcoholic fatty liver disease","author":"Dougherty","year":"2020","journal-title":"Ann Pharmacother"},{"key":"R128-20250603","first-page":"27511233","article-title":"A systematic review of newer antidiabetic agents in the treatment of nonalcoholic fatty liver disease","author":"Dougherty","year":"2020","journal-title":"Ann Pharmacother"},{"key":"R129-20250603","doi-asserted-by":"crossref","first-page":"212264","DOI":"10.7573\/dic.212264","article-title":"Sodium-glucose co-transporter 2 (SGLT2) inhibitors: a growing class of antidiabetic agents","volume":"3","author":"Vivian","year":"2014","journal-title":"Drugs Context"},{"key":"R130-20250603","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1111\/jdi.13237","article-title":"Effects of SGLT2 inhibitors on nonalcoholic fatty liver disease in patients with type 2 diabetes: a meta-analysis of randomized controlled trials","volume":"11","author":"Xing","year":"2020","journal-title":"J Diabetes Investig"},{"key":"R131-20250603","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1007\/s10620-019-5477-1","article-title":"Empagliflozin for the treatment of nonalcoholic steatohepatitis in patients with type 2 diabetes mellitus","volume":"65","author":"Lai","year":"2020","journal-title":"Dig Dis Sci"},{"key":"R132-20250603","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.coph.2020.06.001","article-title":"Evolving understanding of cardiovascular protection by SGLT2 inhibitors: Focus on renal protection, myocardial effects, uric acid, and magnesium balance","volume":"54","author":"Ray","year":"2020","journal-title":"Curr Opin Pharmacol"},{"key":"R133-20250603","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/S2213-8587(18)30023-8","article-title":"Dulaglutide as add-on therapy to SGLT2 inhibitors in patients with inadequately controlled type 2 diabetes (AWARD-10): a 24-week, randomised, double-blind, placebo-controlled trial","volume":"6","author":"Ludvik","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"key":"R134-20250603","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1007\/s13300-018-0455-8","article-title":"Ipragliflozin add-on therapy to a GLP-1 receptor agonist in Japanese patients with type 2 diabetes (AGATE): a 52-week open-label study","volume":"9","author":"Ishihara","year":"2018","journal-title":"Diabetes Ther"},{"key":"R135-20250603","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.jceh.2019.06.003","article-title":"Antidiabetic drugs and statins in nonalcoholic fatty liver disease","volume":"9","author":"Kothari","year":"2019","journal-title":"J Clin Exp Hepatol"},{"key":"R136-20250603","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.jhep.2015.05.006","article-title":"Statin use and non-alcoholic steatohepatitis in at risk individuals","volume":"63","author":"Dongiovanni","year":"2015","journal-title":"J Hepatol"},{"key":"R137-20250603","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1053\/j.gastro.2009.01.053","article-title":"Statins are associated with a reduced risk of hepatocellular carcinoma in a large cohort of patients with diabetes","volume":"136","author":"El-Serag","year":"2009","journal-title":"Gastroenterology"},{"key":"R138-20250603","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/j.jhep.2017.10.018","article-title":"Statin use and the risk of hepatocellular carcinoma in patients at high risk: A nationwide nested case-control study","volume":"68","author":"Kim","year":"2018","journal-title":"J Hepatol"},{"key":"R139-20250603","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1152\/physrev.00010.2008","article-title":"Role of bile acids and bile acid receptors in metabolic regulation","volume":"89","author":"Lefebvre","year":"2009","journal-title":"Physiol Rev"},{"key":"R140-20250603","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1053\/j.gastro.2013.05.042","article-title":"Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease","volume":"145","author":"Mudaliar","year":"2013","journal-title":"Gastroenterology"},{"key":"R141-20250603","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/S0140-6736(14)61933-4","article-title":"Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial","volume":"385","author":"Neuschwander-Tetri","year":"2015","journal-title":"Lancet"},{"key":"R142-20250603","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1016\/S0140-6736(19)33041-7","article-title":"Obeticholic acid for the treatment of non-alcoholic steatohepatitis: Interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial","volume":"394","author":"Younossi","year":"2019","journal-title":"Lancet"},{"key":"R143-20250603","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1111\/apt.14492","article-title":"Clinical and metabolic effects associated with weight changes and obeticholic acid in non-alcoholic steatohepatitis","volume":"47","author":"Hameed","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"R144-20250603","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jhep.2019.10.006","article-title":"Impact of obeticholic acid on the lipoprotein profile in patients with non-alcoholic steatohepatitis","volume":"72","author":"Siddiqui","year":"2020","journal-title":"J Hepatol"},{"key":"R145-20250603","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1111\/liv.14209","article-title":"CONTROL: a randomized phase 2 study of obeticholic acid and atorvastatin on lipoproteins in nonalcoholic steatohepatitis patients","volume":"39","author":"Pockros","year":"2019","journal-title":"Liver Int"},{"key":"R146-20250603","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1007\/s00125-018-4805-x","article-title":"The PNPLA3 rs738409 C>G variant interacts with changes in body weight over time to aggravate liver steatosis, but reduces the risk of incident type 2 diabetes","volume":"62","author":"Xia","year":"2019","journal-title":"Diabetologia"},{"key":"R147-20250603","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1002\/hep.24123","article-title":"Patatin-like phospholipase domain-containing 3 I148M polymorphism, steatosis, and liver damage in chronic hepatitis C","volume":"53","author":"Valenti","year":"2011","journal-title":"Hepatology"},{"key":"R148-20250603","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1002\/hep.26445","article-title":"Patatin-like phospholipase domain-containing 3 I148M affects liver steatosis in patients with chronic hepatitis B","volume":"58","author":"Vigan\u00f2","year":"2013","journal-title":"Hepatology"},{"key":"R149-20250603","doi-asserted-by":"crossref","first-page":"4130","DOI":"10.1172\/JCI65179","article-title":"Chronic overexpression of PNPLA3I148M in mouse liver causes hepatic steatosis","volume":"122","author":"Li","year":"2012","journal-title":"J Clin Invest"},{"key":"R150-20250603","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1016\/j.jhep.2012.07.030","article-title":"Patatin-like phospholipase domain-containing 3 (PNPLA3) I148M (rs738409) affects hepatic VLDL secretion in humans and in vitro","volume":"57","author":"Pirazzi","year":"2012","journal-title":"J Hepatol"},{"key":"R151-20250603","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1194\/jlr.M011205","article-title":"Pnpla3\/Adiponutrin deficiency in mice does not contribute to fatty liver disease or metabolic syndrome","volume":"52","author":"Basantani","year":"2011","journal-title":"J Lipid Res"},{"key":"R152-20250603","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1002\/hep.27490","article-title":"Transmembrane 6 superfamily member 2 gene variant disentangles nonalcoholic steatohepatitis from cardiovascular disease","volume":"61","author":"Dongiovanni","year":"2015","journal-title":"Hepatology"},{"key":"R153-20250603","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1007\/s00125-011-2348-5","article-title":"Cellular characterisation of the GCKR P446L variant associated with type 2 diabetes risk","volume":"55","author":"Rees","year":"2012","journal-title":"Diabetologia"},{"key":"R154-20250603","doi-asserted-by":"crossref","first-page":"12757","DOI":"10.1038\/ncomms12757","article-title":"MBOAT7 rs641738 increases risk of liver inflammation and transition to fibrosis in chronic hepatitis C","volume":"7","author":"Thabet","year":"2016","journal-title":"Nat Commun"},{"key":"R155-20250603","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1002\/hep.29064","article-title":"The membrane-bound O-acyltransferase domain-containing 7 variant rs641738 increases inflammation and fibrosis in chronic hepatitis B","volume":"65","author":"Thabet","year":"2017","journal-title":"Hepatology"},{"key":"R156-20250603","article-title":"Loss of hepatic Mboat7 leads to liver fibrosis","author":"Thangapandi","year":"2020","journal-title":"Gut"},{"key":"R157-20250603","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1002\/hep.30996","article-title":"Genetic variation in HSD17B13 reduces the risk of developing cirrhosis and hepatocellular carcinoma in alcohol misusers","volume":"72","author":"Stickel","year":"2020","journal-title":"Hepatology"},{"key":"R158-20250603","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1002\/hep.30623","article-title":"A 17-beta-hydroxysteroid dehydrogenase 13 variant protects from hepatocellular carcinoma development in alcoholic liver disease","volume":"70","author":"Yang","year":"2019","journal-title":"Hepatology"},{"key":"R159-20250603","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1002\/hep.30350","article-title":"17-beta hydroxysteroid dehydrogenase 13 is a hepatic retinol dehydrogenase associated with histological features of nonalcoholic fatty liver disease","volume":"69","author":"Ma","year":"2019","journal-title":"Hepatology"},{"key":"R160-20250603","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/j.nut.2014.11.018","article-title":"Vitamin E has a beneficial effect on nonalcoholic fatty liver disease: A meta-analysis of randomized controlled trials","volume":"31","author":"Sato","year":"2015","journal-title":"Nutrition"},{"key":"R161-20250603","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/ajg.2010.299","article-title":"Atorvastatin and antioxidants for the treatment of nonalcoholic fatty liver disease: the St Francis Heart Study randomized clinical trial","volume":"106","author":"Foster","year":"2011","journal-title":"Am J Gastroenterol"}],"container-title":["Chinese Medical Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CM9.0000000000001263","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T16:32:30Z","timestamp":1748968350000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/CM9.0000000000001263"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,14]]},"references-count":161,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/cm9.0000000000001263","relation":{},"ISSN":["0366-6999","2542-5641"],"issn-type":[{"value":"0366-6999","type":"print"},{"value":"2542-5641","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,14]]}}}